Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QL1706 + tyrosine kinase inhibitor
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
QL1706 + tyrosine kinase inhibitor is a combination therapy being evaluated for the treatment of advanced hepatocellular carcinoma (HCC). QL1706 (also known as iparomlimab/tuvonralimab) is a first-in-class bifunctional antibody that simultaneously targets programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). In the HCC-SIGHT platform trial conducted by Fudan University, QL1706 is combined with a tyrosine kinase inhibitor (TKI), specifically either lenvatinib or regorafenib. This combination aims to leverage the synergistic effects of dual checkpoint inhibition and anti-angiogenic/multi-kinase inhibition to overcome resistance and improve outcomes in HCC patients who have failed first-line therapy.
- Other names
- Iparomlimab and Tuvonralimab + TKIQL1706 + TKI
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)FGFR (FGFR family)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFR (PDGFR family)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR (VEGFR family)
Beyond the preview
Go deeper on QL1706 + tyrosine kinase inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QL1706 + tyrosine kinase inhibitor.